Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$9.24
Change (%) Stock is Down 0.01 (0.00%)
Volume11,171
Data as of December 11, 2017 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

Upcoming Events

There are currently no events scheduled.
More >>

Presentation

DateTitle
November 7, 2017
Download Documentation Investor Presentation – November 2017

Lastest News

November 6, 2017 - Edge Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference
Read More
November 1, 2017 - Edge Therapeutics Reports Third Quarter 2017 Financial Results
Read More
October 18, 2017 - Edge Therapeutics Announces Third Quarter Financial Results Conference Call on November 1, 2017
Read More

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts